Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study (vol 386, pg 1537, 2015)

被引：0
|
作者：
Roth, D.
Nelson, D. R.
Bruchfeld, A.
机构：
来源：
LANCET | 2015年 / 386卷 / 10006期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1824 / 1824
页数：1
相关论文
共 50 条
  • [41] Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study
    Edward J. Gane
    Edwin DeJesus
    Ewa Janczewska
    Jacob George
    Moises Diago
    Mariliza Hendrique Da Silva
    Henk Reesink
    Igor Nikitin
    Holger Hinrichsen
    Stefan Bourgeois
    Peter Ferenci
    Umesh Shukla
    Ronald Kalmeijer
    Oliver Lenz
    Bart Fevery
    Chris Corbett
    Maria Beumont
    Wolfgang Jessner
    BMC Infectious Diseases, 17
  • [42] Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study
    Norio Hayashi
    Makoto Nakamuta
    Tetsuo Takehara
    Hiromitsu Kumada
    Akiko Takase
    Anita Yee Mei Howe
    Steven W. Ludmerer
    Niloufar Mobashery
    Journal of Gastroenterology, 2016, 51 : 390 - 403
  • [43] Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study
    Gane, Edward J.
    DeJesus, Edwin
    Janczewska, Ewa
    George, Jacob
    Diago, Moises
    Da Silva, Mariliza Hendrique
    Reesink, Henk
    Nikitin, Igor
    Hinrichsen, Holger
    Bourgeois, Stefan
    Ferenci, Peter
    Shukla, Umesh
    Kalmeijer, Ronald
    Lenz, Oliver
    Fevery, Bart
    Corbett, Chris
    Beumont, Maria
    Jessner, Wolfgang
    BMC INFECTIOUS DISEASES, 2017, 17
  • [44] Health-related quality of life in genotype 1 treatment-naive chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study
    Vera-Llonch, M.
    Martin, M.
    Aggarwal, J.
    Donepudi, M.
    Bayliss, M.
    Goss, T.
    Younossi, Z.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 38 (02) : 124 - 133
  • [45] EFFICACY AND SAFETY OF MK-5172 PLUS RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION: FINAL RESULTS OF THE C-SPIRIT STUDY
    Gane, E.
    Ben Ari, Z.
    Mollison, L.
    Zuckerman, E.
    Bruck, R.
    Baruch, Y.
    Wahl, J.
    Bhanja, S.
    Hwang, P.
    Zhao, Y.
    Robertson, M. N.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S499 - S499
  • [46] Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study
    Hayashi, Norio
    Nakamuta, Makoto
    Takehara, Tetsuo
    Kumada, Hiromitsu
    Takase, Akiko
    Howe, Anita Yee Mei
    Ludmerer, Steven W.
    Mobashery, Niloufar
    JOURNAL OF GASTROENTEROLOGY, 2016, 51 (04) : 390 - 403
  • [47] Real-World Cost-Effectiveness Of Elbasvir/Grazoprevir (EBR/GZR) In Treatment-Naive (TN) Patients With Chronic Hepatitis C (CHC) Virus Genotype 1 (GT1) In The United States (US)
    Corman, Shelby L.
    Bacon, Bruce
    Curry, Michael P.
    Dieterich, Douglas T.
    Flamm, Steven L.
    Jiang, Yiling
    Kowdley, Kris V.
    Milligan, Scott
    Nwankwo, Chizoba
    Tsai, Naoky C.
    Younossi, Zobair M.
    Afdhal, Nezam H.
    HEPATOLOGY, 2017, 66 : 621A - 621A
  • [48] Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial
    Bruchfeld, Annette
    Roth, David
    Martin, Paul
    Nelson, David R.
    Pol, Stanislas
    Londono, Maria-Carlota
    Monsour, Howard, Jr.
    Silva, Marcelo
    Hwang, Peggy
    Arduino, Jean-Marie
    Robertson, Michael
    Bach-Yen Nguyen
    Wahl, Janice
    Barr, Eliav
    Greaves, Wayne
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (08): : 585 - 594
  • [49] Efficacy and safety of elbasvir/grazoprevir in treatment-naive patients with chronic HCVGT 1, GT 4 and GT 6 infection (C-CORAL): a phase III randomized multinational clinical trial
    Wei, L.
    Zhdanov, K.
    Burnevich, E.
    Sheen, I-S.
    Heo, J.
    Nguyen, V. K.
    Tanwandee, T.
    Cheng, P. -N.
    Kim, D. Y.
    Tak, W. Y.
    Kizhlo, S.
    Zhongping, D.
    Peng, C. -Y.
    Liang, L. W.
    Evans, B.
    Hanna, G.
    Barr, E.
    Robertson, M.
    Ingravallo, P.
    Talwani, R.
    George, J.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S529 - S529
  • [50] Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled study
    GianPiero Benetti
    Mauro Borzio
    Giuliano Ramella
    Giorgio Bellati
    Silvia Fargion
    Alberto Colombo
    Guido Croce
    Carlo Iamoletti
    Federico Balzola
    Mario Rizzetto
    Internal and Emergency Medicine, 2006, 1 : 113 - 118
12345